Biotech entered the year with renewed optimism, fresh M&A activity, and momentum from January’s JP Morgan Healthcare Conference. But is this new wave of 2026 biotech investment setting up cell and gene therapy for sustainable progress, or fueling another hype cycle?

In this session of Advanced Therapies Think Tank, host Sven Kili leads a conversation with Carol Houts and fellow panelists Miguel Forte, Laura Rodriguez, and Ingrid Gafanhão on how funding is shifting across private, public, strategic, and global sources, and what smarter investing in advanced therapies should actually look like.

Watch the full conversation below, produced by IBTV and supported by the BCA Advanced Therapies Network.